We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00739661
First Posted: August 22, 2008
Last Update Posted: June 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Genentech, Inc.
Results First Submitted: February 10, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg
Drug: Placebo to vismodegib

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Vismodegib 150 mg Patients received vismodegib 150 mg orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
Placebo to Vismodegib Patients received placebo to vismodegib orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.

Participant Flow:   Overall Study
    Vismodegib 150 mg   Placebo to Vismodegib
STARTED   52   52 
COMPLETED   6   10 
NOT COMPLETED   46   42 
Adverse Event                2                0 
Physician decision to withdraw patient                1                0 
Patient decision to withdraw                9                4 
Disease progression, radiographic                33                37 
Reason for discontinuation not available                1                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Vismodegib 150 mg Patients received vismodegib 150 mg orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
Placebo to Vismodegib Patients received placebo to vismodegib orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
Total Total of all reporting groups

Baseline Measures
   Vismodegib 150 mg   Placebo to Vismodegib   Total 
Overall Participants Analyzed 
[Units: Participants]
 52   52   104 
Age 
[Units: Years]
Mean (Standard Deviation)
 57.3  (10.2)   58.6  (8.9)   57.9  (9.6) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      52 100.0%      52 100.0%      104 100.0% 
Male      0   0.0%      0   0.0%      0   0.0% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression-free Survival (PFS)   [ Time Frame: From randomization date through the data cut-off date of May 15, 2010, up to 100 weeks ]

2.  Secondary:   Progression-free Survival (PFS) in Patients With Versus Without Hedgehog Antigen Tumor Expression   [ Time Frame: From randomization date through the data cut-off date of May 15, 2010, up to 100 weeks ]

3.  Secondary:   Overall Survival   [ Time Frame: From randomization date through the data cut-off date of May 15, 2010, up to 100 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Communications
Organization: Genentech, Inc
phone: 800-821-8590



Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00739661     History of Changes
Other Study ID Numbers: SHH4489g
First Submitted: August 21, 2008
First Posted: August 22, 2008
Results First Submitted: February 10, 2012
Results First Posted: April 26, 2012
Last Update Posted: June 8, 2017